Orchestra BioMed Holdings (Orchestra BioMed Holdings) Cash-to-Debt : 51.92 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Orchestra BioMed Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Orchestra BioMed Holdings's cash to debt ratio for the quarter that ended in Dec. 2023 was 51.92.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Orchestra BioMed Holdings could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Orchestra BioMed Holdings's Cash-to-Debt or its related term are showing as below:

OBIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.92 Med: 5.42 Max: 51.92
Current: 51.92

During the past 4 years, Orchestra BioMed Holdings's highest Cash to Debt Ratio was 51.92. The lowest was 1.92. And the median was 5.42.

OBIO's Cash-to-Debt is ranked better than
73.05% of 1540 companies
in the Biotechnology industry
Industry Median: 6.485 vs OBIO: 51.92

Orchestra BioMed Holdings Cash-to-Debt Historical Data

The historical data trend for Orchestra BioMed Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Orchestra BioMed Holdings Cash-to-Debt Chart

Orchestra BioMed Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

3.79

1.92

7.06

51.92

Orchestra BioMed Holdings Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial						7.06	10.84	10.15	9.50	51.92

Competitive Comparison of Orchestra BioMed Holdings's Cash-to-Debt

For the Biotechnology subindustry, Orchestra BioMed Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orchestra BioMed Holdings's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Orchestra BioMed Holdings's Cash-to-Debt falls into.

Orchestra BioMed Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Orchestra BioMed Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	87.595	/	(0.649	+	1.038)
	=	51.92

Orchestra BioMed Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	87.595	/	(0.649	+	1.038)
	=	51.92

Orchestra BioMed Holdings (NAS:OBIO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Orchestra BioMed Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Orchestra BioMed Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Orchestra BioMed Holdings (Orchestra BioMed Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchestra BioMed Holdings Inc (NAS:OBIO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 Union Square Drive,, New Hope, PA, USA, 18938

Website

https://www.orchestrabiomed.com

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Executives

George Papandreou	officer: See Remarks	C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Eric S Fain	director	ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
David P Hochman	director, officer: See Remarks	15 WESTON HILL RD., RIVERSIDE CT 06878
Joshua Aiello	officer: Principal Accounting Officer	150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Yuval Mika	officer: See Remarks	150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Pamela Ann Connealy	director	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Darren Sherman	director, officer: See Remarks	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Rose Eric A Md	director	161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Andrew Lawrence Taylor	officer: Chief Financial Officer	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
William Reed Little	officer: See Remarks	C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Plc Medtronic	10 percent owner	20 ON HATCH, LOWER HATCH STREET, DUBLIN L2 2
Michael Kaswan	officer: Chief Financial Officer	KBL HEALTHCARE ACQUISITION CORP II, 645 MADISON AVENUE, NEW YORK NY 10022
Geoffrey Wade Smith	director	6740 SHADY OAK ROAD, EDEN PRAIRIE MN 55344
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014